0000000000326674

AUTHOR

Jan Lehmann

showing 1 related works from this author

Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.

2005

OBJECTIVES To report the long-term follow-up of patients with locally advanced bladder cancer treated with either adjuvant combined chemotherapy with methotrexate, vinblastine, doxorubicin/epirubicin, and cisplatin (MVAC/MVEC) or no additional treatment after radical cystectomy, to examine various survival endpoints and factors associated with long-term survival. PATIENTS AND METHODS Between May 1987 and December 1990, 49 patients undergoing radical cystectomy for locally advanced bladder cancer were randomized to observation only or adjuvant systemic chemotherapy with three cycles of MVAC/MVEC (methotrexate 30 mg/m2 on day 1, 15 and 22; vinblastine 3 mg/m2 on day 2, 15 and 22; doxorubicin …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentUrologyCystectomyVinblastineDisease-Free SurvivalCystectomyAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAgedEpirubicinChemotherapyBladder cancerbusiness.industryHazard ratioCombination chemotherapyMiddle Agedmedicine.diseaseInterim analysisCombined Modality TherapyVinblastineSurgeryMethotrexateTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinLymphatic MetastasisFemaleCisplatinNeoplasm Recurrence Localbusinessmedicine.drugEpirubicinFollow-Up StudiesBJU international
researchProduct